One thing that is unlikely to change under the new Administration is the goal of reducing the cost of healthcare through various alternative payment initiatives. Here’s how that will affect oncology.
Michael L. Blau, Esq.
Advertisement
Michael L. Blau is a healthcare partner at Foley & Lardner LLP in the firm’s Boston office, and is cofounder of the Cancer Center Business Summit (www.cancerbusinesssummit.com). He focuses his practice on advising clients on healthcare transactional, corp
Articles by Michael L. Blau, Esq.
Advertisement
Latest Updated Articles
- Regulatory changes for community oncology: What health execs should know
Published: April 14th 2017 | Updated:
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
In America, Aging With HIV is a Continuous Challenge
2
Beyond the Primary End Point: Diving Deeper into the EMERALD trial | Written Recap
3
What Health Plans Should Ask For in Their PBM Contracts If They Want Transparency | AMCP Nexus 2025
4
